Software Transparency in 2024: The Regulatory Convergence That Is Reshaping the Industry

The Regulatory Stack

Large software organizations now operate under multiple overlapping SBOM and software transparency regimes simultaneously. A U.S. company that sells software to federal agencies, has EU customers, processes payments, and serves financial institution clients may be simultaneously subject to EO 14028/OMB M-22-18 (federal contracting), EU CRA (EU market access), PCI DSS 4.0 (payment processing), and DORA (financial sector clients). Each framework has its own requirements, terminology, and compliance timelines — but the underlying capability they all demand is the same: accurate software component inventories.

The Shared Foundation

The good news in this complexity is that the underlying technical capability — automated SBOM generation and continuous vulnerability monitoring — satisfies all of these frameworks from a single program. An organization that builds a comprehensive SBOM program is not building four separate compliance programs; it is building one technical capability that produces evidence for all four. This efficiency makes the investment case for SBOM tooling straightforward even for organizations skeptical of individual regulatory requirements.

Where the Frameworks Diverge

The differences across frameworks are primarily in the reporting, disclosure, and response obligations rather than in the underlying component inventory requirement. EO 14028 requires SBOM delivery to federal customers. EU CRA requires vulnerability reporting to ENISA within 24 hours of exploited vulnerability discovery. FDA requires SBOM inclusion in premarket submissions and postmarket monitoring programs. PCI DSS 4.0 requires an internal component inventory used for vulnerability management. DORA requires ICT dependency registers for regulatory examination. Understanding these surface differences — and building the workflows to satisfy each — is the compliance engineering work that organizations must complete on top of the shared SBOM foundation.

Enforcement Risk Is Real

With multiple frameworks now in force, the question has shifted from "when will we need to comply?" to "what is the enforcement risk?" The FDA has already refused premarket submissions lacking cybersecurity documentation. EU CRA enforcement authority will reside with national market surveillance authorities, and non-compliant products cannot be placed on the EU market. PCI DSS non-compliance carries financial penalties from card brands. The compliance window has closed — 2024 was the year enforcement became real.